Preliminary data suggests significantly reduced pain and opioid use among patients treated with cryoneurolysis prior to total knee replacement, Myoscience Inc suggests. The results are being presented at the 2019 American Academy of Orthopaedic Surgeons (AAOS) Annual...
Myoscience Inc has entered into a definitive agreement to be acquired by Pacira Pharmaceuticals Inc for up to $220 million. The transaction is expected to close by early April 2019. The iovera° system will be part of the Pacira non-opioid product portfolio, according...
Myoscience Inc announces the commercial launch of the iovera° Smart Tip 309, a significant addition to the iovera° system, according to the company. The iovera° system treats the genicular (knee) nerves through a process called cryoneurolysis and provides immediate...
Myoscience Inc announces the commercial release of its Nerve Stim Enabled Smart Tip 1x90mm, the latest addition to its iovera° system. This tip received FDA 510(k) clearance in early 2018. The iovera° system is a non-opioid platform technology engineered to help...
